EGFR and non-small cell lung carcinoma: Case reports from a phase I trial evaluating a combination of cetuximab and erlotinib also identified a remarkable 3.5 years PFS for one NSCLC patient harboring a D770> GY exon 20 insertion, highlighting the possibility of durable responses to mAb and EGFR kinase inhibitors for certain patients with EGFR exon 20 insertions [64,66].